Trials / Completed
CompletedNCT02452190
Study of Reslizumab in Participants With Uncontrolled Asthma and Elevated Blood Eosinophils
A 52-Week Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Reslizumab 110 mg Fixed, Subcutaneous Dosing in Patients With Uncontrolled Asthma and Elevated Blood Eosinophils
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 468 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to determine the effect of reslizumab (110 mg) administered subcutaneously every 4 weeks on clinical asthma exacerbations in adults and adolescents with asthma and elevated blood eosinophils who are inadequately controlled on standard-of-care asthma therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Reslizumab | Reslizumab will be administered subcutaneously in a dose of 110 mg every 4 weeks. |
| DRUG | Placebo | Matching Placebo |
Timeline
- Start date
- 2015-09-28
- Primary completion
- 2017-12-04
- Completion
- 2018-01-31
- First posted
- 2015-05-22
- Last updated
- 2021-11-09
- Results posted
- 2019-02-06
Locations
226 sites across 21 countries: United States, Argentina, Australia, Belgium, Canada, Czechia, France, Germany, Hungary, Israel, Japan, Mexico, New Zealand, Poland, Romania, Russia, South Africa, South Korea, Spain, Turkey (Türkiye), Ukraine
Source: ClinicalTrials.gov record NCT02452190. Inclusion in this directory is not an endorsement.